Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $229.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.09M
Average 0.11M
Returns on capital
Surrozen, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
128.9%
avg 9.4%
ROIC
-46.7%
avg -62.0%
ROA
-245.1%
avg -94.0%
Analysis
ROE is currently the strongest return metric at 128.9% versus its period average of 9.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Craig C. Parker | Chief Executive Officer, President & Director | USD 976.5K | 64 | 18.18K | 0.24% |
Charles Williams | Chief Operating Officer & Corporate Secretary | USD 689.79K | 46 | — | — |
Yang Li | Executive Vice President of Research | USD 642.1K | 57 | 18.88K | 0.25% |
Esther Jhun | Controller | — | — | — | — |
Andrew Maleki | Chief Financial Officer | — | 36 | — | — |
Michael Lauw | Senior Vice President of Development Operations | — | — | — | — |
Calvin Kuo | Co-Founder & Member of Scientific Advisory Board | — | — | — | — |
K. Christopher Garcia | Co-Founder & Member of Scientific Advisory Board | — | — | — | — |
Roeland Nusse | Co-Founder & Member of Scientific Advisory Board | — | 76 | — | — |
Daniel L. Chao | Vice President and Head of Clinical Development | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
52
$8.87M
Sells
7
$7.23M
Net Transaction Value
+$1.64M
Net buying
Most Active
TCG Crossover GP II, LLC
22 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 22, 26Jul 22, 2026 | TCG Crossover GP II, LLC Indirect | Sell | $3.5M$3,453,125.00 |
| Jul 22, 26Jul 22, 2026 | TCG Crossover GP II, LLC Indirect | Sell | $3.5M$3,453,125.00 |
| May 4, 26May 4, 2026 | Li Yang Direct | Sell | $52.8K$52,799.16 |
| May 4, 26May 4, 2026 | Parker Craig C Direct | Sell | $150.8K$150,797.59 |
| May 4, 26May 4, 2026 | Williams Charles O Direct | Sell | $67.9K$67,865.58 |
| Mar 24, 26Mar 24, 2026 | TCG Crossover GP II, LLC Indirect | Buy | $1.3M$1,316,858.33 |
| Mar 24, 26Mar 24, 2026 | TCG Crossover GP II, LLC Indirect | Buy | $1.3M$1,316,858.33 |
| Mar 23, 26Mar 23, 2026 | TCG Crossover GP II, LLC Indirect | Buy | $189.5K$189,513.14 |
| Mar 23, 26Mar 23, 2026 | TCG Crossover GP II, LLC Indirect | Buy | $189.5K$189,538.04 |
| Mar 16, 26Mar 16, 2026 | TCG Crossover GP II, LLC Indirect | Buy | $14.9K$14,866.49 |
1–10 of 59
Summary
Insiders reported 52 buys worth $8.87M and 7 sells worth $7.23M over the last 12 months. That adds up to net buying of $1.64M. TCG Crossover GP II, LLC was the most active insider with 22 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -34.7% | -9.6% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -34.7% over three years. Forward estimates point to Revenue at -9.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Surrozen, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about SRZN's management, answered from reported figures.
Who manages SRZN?
Surrozen, Inc. (SRZN) lists 10 active executives. The top listed executive is Esther Jhun, Controller.
Are SRZN insiders buying or selling?
Recent insider activity shows net buying of $92.57M.
Continue the stock analysis
Jump to another research area for this company.